New Platelet Aggregation Inhibitor for Cardiovascular Care
The aim of the portrayed invention is to develop and make new drugs for the primary- and secondary prophylaxis of thrombosis complications as well as the general treatment of cardiovascular diseases available, using inhibitors of the multidrug resistance protein (MRP) in human platelets, more specifically of MRP4.
Further Information: PDF
PVA Mecklenburg-Vorpommern AG
Phone: +49 (0)381/49 74 74 0
Contact
Antonio Martinez
